Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

51533 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma

NCT00736801

Allergic Asthma

COMPLETED NA

Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)

NCT00284856

Asthma

COMPLETED PHASE3

Montelukast for Patients With Obstructive Sleep Apnea Syndrome

NCT03545997

Sleep Apnea, Obstructive

TERMINATED PHASE3

Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

NCT01332357

Asthma

COMPLETED

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)

NCT00383552

Asthma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) intramural research program. This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Montelukast

Exposure group

Montelukast

Intervention Type DRUG

Montelukast claim is used as the exposure group.

Fluticasone

Reference group

Fluticasone

Intervention Type DRUG

Fluticasone claim is used as the reference group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Montelukast

Montelukast claim is used as the exposure group.

Intervention Type DRUG

Fluticasone

Fluticasone claim is used as the reference group.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Aged \>/= 65 years on the index date
* 2\. No prior use of Montelukast and Fluticasone anytime prior to cohort entry date
* 3\. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
* 4\. At least two claims with asthma diagnosis measured 365 days prior to drug init

Exclusion Criteria

* 1\. Prior history of dementia measured anytime prior to cohort entry date
* 2\. Prior history of nursing home admission in the 365 days prior to the cohort entry date

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes